Showing results (1-10 of 56) with videos related to
Sort By:
Pageof 6
European Journal of Clinical Pharmacology|October 17, 2009
Novel therapeutic strategies in Parkinson's diseasePeter Klivenyi, Laszlo VecseiMethods in Molecular Biology (Clifton, N.J.)|September 14, 2011
Pharmacological models of Parkinson's disease in rodentsPeter Klivenyi, Laszlo VecseiBiomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 26, 2009
Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's diseaseEniko Vamos, Krisztina Voros, Laszlo Vecsei, et al.Neurological Research|September 5, 2008
Effects of valproate on the dopaminergic system in miceEniko Vamos, Anett Csati, Laszlo Vecsei, et al.CNS & Neurological Disorders Drug Targets|March 14, 2019
Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar AtaxiasLaszlo Szpisjak, Denes Zadori, Peter Klivenyi, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|June 25, 2009
Neuroprotective effects of probenecid in a transgenic animal model of Huntington's diseaseEniko Vamos, Krisztina Voros, Denes Zadori, et al.Journal of the Neurological Sciences|March 10, 2009
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotectionEniko Vamos, Arpad Pardutz, Peter Klivenyi, et al.European Neurology|November 25, 2003
Alpha-tocopherol and NADPH in the erythrocytes and plasma of multiple sclerosis patients. Effect of interferon-beta-1b treatmentEszter Karg, Peter Klivenyi, Krisztina Bencsik, et al.Neuroscience Letters|May 10, 2017
Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosisLevente Szalardy, Denes Zadori, Krisztina Bencsik, et al.Neurochemical Research|December 13, 2005
Effects of mitochondrial toxins on the brain amino acid concentrationsPeter Klivenyi, Katalin A Kekesi, Zsuzsanna Hartai, et al.Pageof 6